<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874832</url>
  </required_header>
  <id_info>
    <org_study_id>STS101-001</org_study_id>
    <nct_id>NCT03874832</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-Label, Crossover Study to Evaluate the PK, Bioavailability, Dose Proportionality, Safety, and Tolerability of Single Doses of STS101, DHE Mesylate IM Injection and DHE Mesylate Nasal Spray in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Satsuma Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Satsuma Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center, single-dose, open-label, 2-part, 3-period crossover (in each part),
      pharmacokinetic and safety study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1, open-label, 2-part, single-dose pharmacokinetic and safety study of STS101 in
      healthy subjects. Part 1 was designed to identify a dose level of STS101 for administration
      in Part 2. Subjects in Part 1 received 3 ascending doses of STS101 in a 3-period crossover
      manner. During Part 2, subjects received the dose of STS101 selected from Part 1, 1.0 mg DHE
      mesylate IM injection, and 2 mg DHE mesylate nasal spray in a randomized, 3 period crossover
      manner.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2018</start_date>
  <completion_date type="Actual">November 7, 2018</completion_date>
  <primary_completion_date type="Actual">November 7, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>STS101 Dose Selection - Part 1</measure>
    <time_frame>Pre-dose through 48 hours post-dose</time_frame>
    <description>To select a dose level of STS101 for further evaluation in Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DHE Relative Bioavailability - Part 2</measure>
    <time_frame>Pre-dose through 48 hours post-dose</time_frame>
    <description>To assess the relative bioavailability of dihydroergotamine following a single dose of STS101 at the dose level selected in Part 1 compared to a single dose of 1 mg DHE administered by intramuscular injection and 2 mg DHE administered as nasal spray</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DHE Area Under the Curve [AUC] - Part 1</measure>
    <time_frame>Pre-dose through 48 hours post-dose</time_frame>
    <description>To describe the pharmacokinetic profile based on the AUC of dihydroergotamine following single dose administration of 1.5 mg, 3.0 mg and 6.0 mg of STS101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8'OH-DHE Area Under the Curve [AUC] - Part 1</measure>
    <time_frame>Pre-dose through 48 hours post-dose</time_frame>
    <description>To describe the pharmacokinetic profile based on the AUC of 8'hydroxydihydroergotamine (8'OH-DHE) following single dose administration of 1.5 mg, 3.0 mg and 6.0 mg of STS101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events - Parts 1 &amp; 2</measure>
    <time_frame>Pre-dose through 48 hours post-dose</time_frame>
    <description>To assess the safety profile through examination of serious adverse events of single doses of STS101; 1 mg DHE administered by intramuscular injection, and 2 mg DHE administered as nasal spray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Adverse Events - Parts 1 &amp; 2</measure>
    <time_frame>Pre-dose through 48 hours post-dose</time_frame>
    <description>To assess the safety profile through examination of treatment-related adverse events of single doses of STS101; 1 mg DHE administered by intramuscular injection, and 2 mg DHE administered as nasal spray</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Migraine With Aura</condition>
  <condition>Migraine Without Aura</condition>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>STS101 1.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STS101 (dihydroergotamine nasal powder), 1.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STS101 3.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STS101 (dihydroergotamine nasal powder), 3.0 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STS101 6.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STS101 (dihydroergotamine nasal powder), 6.0 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHE intramuscular injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dihydroergotamine mesylate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHE nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dihydroergotamine mesylate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroergotamine</intervention_name>
    <description>Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.</description>
    <arm_group_label>DHE intramuscular injection</arm_group_label>
    <arm_group_label>DHE nasal spray</arm_group_label>
    <arm_group_label>STS101 1.5 mg</arm_group_label>
    <arm_group_label>STS101 3.0 mg</arm_group_label>
    <arm_group_label>STS101 6.0 mg</arm_group_label>
    <other_name>Dihydroergotamine Mesylate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 50 years of age at the time of enrollment.

          -  Signed the informed consent document.

          -  Subject judged to be healthy by a qualified physician

        Exclusion Criteria:

          -  Abnormal physical findings of clinical significance at the screening examination

          -  Significant abnormal laboratory values at the Screening Visit.

          -  Clinically significant symptoms or conditions that may have placed the subject at an
             unacceptable risk as a participant in the trial, or that may have interfered with the
             absorption, distribution, metabolism or excretion of the IMP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey A Levy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences Miami Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences Miami Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dihydroergotamine</keyword>
  <keyword>dihydroergotamine mesylate</keyword>
  <keyword>migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
    <mesh_term>Migraine without Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihydroergotamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

